BRINEURA® is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.1
KUVAN® is indicated for the treatment of hyperphenylalaninemia (HPA) by reducing blood phenylalanine levels in patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.2
NAGLAZYME® is indicated for the treatment of Mucopolysaccharidosis VI (MPS VI) storage disorder, a disease in which the enzyme level of N-acetylgalactosamine 4-sulfatase is absent or lower than normal.3
PALYNZIQ® is indicated for the treatment of patients with phenylketonuria (PKU) aged 16 and older, whose blood phenylalanine levels cannot be adequately controlled by other means such as by diet.4
VIMIZIM® is indicated for the treatment of MPS IVA (Mucopolysaccharidosis Type IVA, Morquio A Syndrome).5
VOXZOGO® is indicated for the treatment of achondroplasia in paediatric patients whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.6
Registered pharmacies and hospitals only: Patients and consumers should speak to their community pharmacy or prescriber for more information.
DHL Direct to Market
Toll Free: 1800 077 421 (Option 1)
Email: d2mcs@dhl.com
Healthcare Logistics
Ph: 09 969 0734
E-mail: orders@healthcarelogistics.co.nz